Compare Gilead Sciences, Inc. (GILD) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PayPal Holdings, Inc. — how do they compare? Gilead Sciences, Inc. trades at $151.28 (market cap $182.40B), while PayPal Holdings, Inc. trades at $55.49 (market cap $47.07B). The key difference: Gilead Sciences, Inc. is far larger — about 3.9× PayPal Holdings, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and PayPal Holdings, Inc. for 106 Days on average.
| GILD | PYPL | |
|---|---|---|
Market Cap | $182.40B | $47.07B |
Volume | 4,469,821 | 13,860,099 |
Sector | Health | Financials |
52-Week High | $155.80 | $75.75 |
52-Week Low | $116.74 | $39.08 |
Typical Hold Time | 111 Days | 106 Days |
Enterprise Value | $205.46B | $49.21B |
Dividend Yield | 2.23% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
PayPal (PYPL) trades at $55.47, up 0.95% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.4, net income margin of 14.36%, and consistent revenue growth from $33.17B in 2025 to $34.1B projected for 2026. Recent positive developments include a Meta partnership for AI-powered checkout and three consecutive quarterly earnings beats.
PYPL presents a compelling value opportunity with attractive valuation multiples and solid profitability, though investors face risks from checkout competition and slowing growth. Analyst consensus leans cautious with 60% hold ratings, but the $56.41 price target suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
